Explore the JPMorgan European Discovery Trust's latest performance review, highlighting key sectors and stocks influencing returns as it targets 2025 goals...
Pets at Home Group Plc (LON:PETS) reports Q3 FY25 financials, showing a 2.3% consumer revenue rise to £468.0m, driven by strong Vet Group performance...
Bluefield Solar Income Fund declares a 2.20 pence interim dividend per share for FY ending June 2025, reaffirming its dividend guidance of 8.90 pence...
Molten Ventures plc appoints Andrew Zimmermann as Director and CFO, effective January 2025, marking a pivotal step in the company's financial leadership...
GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results...
Aptamer Group plc reports progress on key projects in its H1 2025 trading update, highlighting partnerships with Unilever and Alzheimer's biomarker validation...
Explore the JPMorgan European Discovery Trust's latest performance review, highlighting key sectors and stocks influencing returns as it targets 2025 goals...
Pets at Home Group Plc (LON:PETS) reports Q3 FY25 financials, showing a 2.3% consumer revenue rise to £468.0m, driven by strong Vet Group performance...
Bluefield Solar Income Fund declares a 2.20 pence interim dividend per share for FY ending June 2025, reaffirming its dividend guidance of 8.90 pence...
Molten Ventures plc appoints Andrew Zimmermann as Director and CFO, effective January 2025, marking a pivotal step in the company's financial leadership...
GSK's depemokimab, an ultra-long-acting biologic, is up for regulatory review in China and Japan for asthma and CRSwNP, based on positive trial results...
Aptamer Group plc reports progress on key projects in its H1 2025 trading update, highlighting partnerships with Unilever and Alzheimer's biomarker validation...
